| 146. |
Interferon lambda 3 haplotype affects treatment response to interferon-alpha and ribavirin combination therapy in chronic hepatitis C. Nature Genetics 2009; 41: 1100-1104. |
| 147. |
A phase 1b placebo-controlled, randomised study of the safety, pharmacokinetics and antiviral activity of p7 inhibitor BIT225 in patients with hepatitis C virus (HCV) infection. Procedings of HepDART Meeting, Hawaii 2009 |
| 148. |
An extended study of appendicectomy as a therapy for ulcerative proctitis. Proceedings of Digestive Diseases Week, New Orleans 2010. |
| 149. |
Management of non-acetaminophen-induced acute liver failure. Nature Reviews Gastroenterology and Hepatology 2010; 7: 75-77. |
| 150. |
Gut flora and hepatic encephalopathy in cirrhosis. New England Journal of Medicine 2010; 362;12: 1140-1142. |
| 151. |
Development of occult hepatitis B in pregnancy: Implications for ante-natal screening in women from endemic areas. Obstetrics Medicine 2010; 3: 115-118. |
| 152. |
Isolation and detection of Campylobacter concisus from saliva of healthy individuals and patients with inflammatory bowel disease. Journal of Clinical Microbiology 2010; 48: 2965-2967. |
| 153. |
Gastroenterology and Hepatology. In: Harris P, Nagy S, Vardaxis N (Eds). Mosby’s Dictionary of Medical, Nursing & Health Professions, 2nd Australian and New Zealand Edition, Elsevier Australia, Sydney, 2010. |
| 154. |
Hepatocellular carcinoma. In: Segal I, Pitchumoni CS, Sung J (Eds). Gastroenterology and Hepatology Without Frontiers: A Clinician’s Guide to a Global Phenomenon, Elsevier Australia, Sydney 2011. |
| 155. |
Alcoholic liver disease. In: Segal I, Pitchumoni CS, Sung J (Eds). Gastroenterology and Hepatology Without Frontiers: A Clinician’s Guide to a Global Phenomenon, Elsevier Australia, Sydney 2011. |
| 156. |
IL28B, HLA-C and KIR variants additively and interactively predict response to therapy in chronic hepatitis C virus infection. Public Library of Science Medicine 2011; In press. |
| 157. |
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine 2011, 3: 57. |
| 158. |
Prevalence of Campylobacter species in adult Crohn’s disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS ONE / Public Library of Science 2011; 6(9): e25417. |
| 159. |
Up-regulation of intestinal epithelial expression of TLR-4, MD-2, COX-2 and IL-8 by Campylobacter concisus: Possible relevance to the pathophysiology of inflammatory bowel disease. 2nd International Conference on Immune Tolerance, Amsterdam, October 2011 |
| 160. |
Angiotensin II receptor inhibition in multifocal inflammatory myofibroblastic tumour of the liver. Proceedings of Tow Research Awards, Sydney, October 2011. |
| 161. |
Investigation of the enteric pathogenic potential of oral Campylobacter concisus strains isolated from patients with inflammatory bowel disease. PLoS ONE/ Public Library of Science 2012; 7: e38217. |
| 162. |
Percutaneous angioplasty and stenting for mesenteric ischaemia. In: Forbes T (Ed). Angioplasty, Various Techniques and Challenges in Treatment of Congenital and Acquired Vascular Stenoses, In Tech, Rijeka, 2012: 1-8. |
| 163. |
The effects of oral and enteric Campylobacter concisus strains on expression of TLR4, MD-2, TLR2, TLR5 and COX-2 in HT-29 cells. PLoS ONE/ Public Library of Science 2013; 8: e56888. |
| 164. |
CCR5-32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes & Immunity 2013; 14: 286-290. |
